Fulcrum Therapeutics Sells $100M in Stock
Ticker: FULC · Form: 8-K · Filed: Aug 22, 2024 · CIK: 1680581
| Field | Detail |
|---|---|
| Company | Fulcrum Therapeutics, INC. (FULC) |
| Form Type | 8-K |
| Filed Date | Aug 22, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-offering, unregistered-sale, financing
TL;DR
Fulcrum just sold $100M in stock at $7/share, closing Aug 26.
AI Summary
Fulcrum Therapeutics, Inc. announced on August 21, 2024, that it entered into a securities purchase agreement for the unregistered sale of approximately $100 million of its common stock. This transaction is expected to close on August 26, 2024, and involves the issuance of 14,285,714 shares at a price of $7.00 per share.
Why It Matters
This unregistered sale of equity securities provides Fulcrum Therapeutics with significant capital, which could be used to fund its ongoing research and development efforts or other corporate initiatives.
Risk Assessment
Risk Level: medium — The sale of a large block of stock at a fixed price, especially an unregistered offering, can dilute existing shareholders and may indicate a need for immediate capital.
Key Numbers
- $100.0M — Gross Proceeds (From unregistered sale of equity securities)
- $7.00 — Price Per Share (For the unregistered sale)
- 14,285,714 — Shares Sold (In the unregistered offering)
Key Players & Entities
- Fulcrum Therapeutics, Inc. (company) — Registrant
- August 21, 2024 (date) — Date of Report
- $100 million (dollar_amount) — Aggregate purchase price
- August 26, 2024 (date) — Expected closing date
- 14,285,714 (number) — Number of shares to be issued
- $7.00 (dollar_amount) — Price per share
FAQ
What is the purpose of this unregistered sale of equity securities?
The filing does not explicitly state the purpose of the unregistered sale, but such transactions typically provide capital for general corporate purposes, including research and development.
Who are the purchasers in this unregistered sale?
The filing refers to a securities purchase agreement but does not name the specific purchasers, indicating they are likely institutional investors or accredited investors.
What are the terms of the securities purchase agreement?
Fulcrum Therapeutics entered into a securities purchase agreement to sell approximately $100 million of common stock at $7.00 per share, with an expected closing on August 26, 2024.
Are there any conditions to closing the sale?
While not detailed in this excerpt, unregistered equity sales typically have customary closing conditions, which may include representations and warranties from the seller.
What is the significance of this being an 'unregistered' sale?
An unregistered sale means the securities are sold without being registered with the SEC, typically to a limited number of accredited investors, exempting the company from certain disclosure and registration requirements.
Filing Stats: 736 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2024-08-22 16:02:59
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share FULC Nasdaq Global Market
Filing Documents
- d98656d8k.htm (8-K) — 26KB
- d98656dex41.htm (EX-4.1) — 70KB
- 0001193125-24-205347.txt ( ) — 237KB
- fulc-20240821.xsd (EX-101.SCH) — 3KB
- fulc-20240821_lab.xml (EX-101.LAB) — 18KB
- fulc-20240821_pre.xml (EX-101.PRE) — 11KB
- d98656d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 22, 2024 Fulcrum Therapeutics, Inc. By: /s/ Alex C. Sapir Alex C. Sapir President and Chief Executive Officer